Global Health Intrinsic Value
Global Health (MEDANTA) median intrinsic value is ₹708.74 from 9 valuation models (range ₹411–₹1570), vs current price ₹1371.00 — -48.3% downside (Trading Above Calculated Value), margin of safety -93.4%. Read MEDANTA dividend yield for the complete payout history and dividend yield track record.
MEDANTA Valuation Methods Summary — DCF, Graham Number & P/E
Global Health intrinsic value across 9 models vs current price ₹1371.00 — upside/downside and value range per method. For current market price and key ratios, visit Global Health share price today.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹411.30 | ₹329.04 - ₹493.56 | -70.0% | EPS: ₹21.44, Sector P/E: 12x |
| Book Value Method | asset | ₹733.70 | ₹660.33 - ₹807.07 | -46.5% | Book Value/Share: ₹733.70, P/B: 1.0x |
| Revenue Multiple Method | revenue | ₹708.74 | ₹637.87 - ₹779.61 | -48.3% | Revenue/Share: ₹885.93, P/S: 0.8x |
| EBITDA Multiple Method | earnings | ₹1248.89 | ₹1124.00 - ₹1373.78 | -8.9% | EBITDA: ₹1124.00Cr, EV/EBITDA: 6x |
| Simple DCF (5Y) | dcf | ₹1569.63 | ₹1255.70 - ₹1883.56 | +14.5% | CF Growth: 15.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹411.30 | ₹370.17 - ₹452.43 | -70.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹411.30 | ₹370.17 - ₹452.43 | -70.0% | Revenue Growth: 6.0%, Adj P/E: 8.2x |
| ROE Based Valuation | profitability | ₹1262.22 | ₹1136.00 - ₹1388.44 | -7.9% | ROE: 14.3%, P/E Multiple: 12x |
| Graham Defensive Method | conservative | ₹594.93 | ₹535.44 - ₹654.42 | -56.6% | EPS: ₹21.44, BVPS: ₹733.70 |
MEDANTA Intrinsic Value vs Market Price — All Valuation Models
Global Health fair value range ₹411–₹1570 vs current market price ₹1371.00 across 9 valuation models. Analyse MEDANTA shareholding pattern to track promoter, FII and institutional holdings.
MEDANTA Intrinsic Value Analysis — Undervalued or Overvalued?
Global Health median intrinsic value ₹708.74, current price ₹1371.00 — Trading Above Calculated Value by 48.3%, margin of safety -93.4%.
What is the intrinsic value of MEDANTA?
Based on our comprehensive analysis using 9 different valuation methods, the estimated intrinsic value of Global Health (MEDANTA) is ₹708.74 (median value). With the current market price of ₹1371.00, this represents a -48.3% variance from our estimated fair value.
The valuation range spans from ₹411.30 to ₹1569.63, indicating ₹411.30 - ₹1569.63.
Is MEDANTA undervalued or overvalued?
Based on our multi-method analysis, Global Health (MEDANTA) appears to be trading above calculated value by approximately 48.3%.
MEDANTA Financial Health — Key Ratios vs Industry Benchmarks
Global Health financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 1.29 | Industry Standard: 2.0+ | Below 1.5 | Measures short-term liquidity capacity |
| Return on Equity | 14.3% | Industry Standard: 15%+ | Above 10% | Measures shareholder return efficiency |
| Operating Margin | 21.0% | Industry Standard: 20%+ | Above 20% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.81x | Industry Standard: 1.0x+ | Above 0.5x | Measures asset utilization efficiency |
MEDANTA Cash Flow Quality — Operating & Free Cash Flow
Global Health operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹624 Cr | ₹264 Cr | Positive Free Cash Flow | 7/10 |
| March 2024 | ₹612 Cr | ₹392 Cr | Positive Free Cash Flow | 8/10 |
| March 2023 | ₹645 Cr | ₹474 Cr | Positive Free Cash Flow | 8/10 |
| March 2022 | ₹311 Cr | ₹101 Cr | Positive Free Cash Flow | 7/10 |
| March 2021 | ₹242 Cr | ₹123 Cr | Positive Free Cash Flow | 8/10 |